Stock RMD RESMED, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials ResMed, Inc.

Equities

RMD

US7611521078

Advanced Medical Equipment & Technology

Market Closed - Nyse
Other stock markets
 04:00:01 2024-04-26 pm EDT 		5-day change 1st Jan Change
218.1 USD +18.89% Intraday chart for ResMed, Inc. +21.92% +26.76%
Apr. 26 Sector Update: Health Care Stocks Edge Higher Late Afternoon MT
Apr. 26 Top Midday Gainers MT

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 17,498 27,776 35,903 30,691 32,133 32,035 - -
Enterprise Value (EV) 1 18,622 28,489 36,263 31,192 33,346 32,557 31,680 30,704
P/E ratio 43.6 x 45 x 76.1 x 39.6 x 35.9 x 31.4 x 26.9 x 24.3 x
Yield 1.23% 0.81% 0.63% 0.8% 0.82% 0.9% 0.98% 1.03%
Capitalization / Revenue 6.71 x 9.39 x 11.2 x 8.58 x 7.61 x 6.86 x 6.38 x 5.96 x
EV / Revenue 7.14 x 9.63 x 11.3 x 8.72 x 7.9 x 6.97 x 6.31 x 5.71 x
EV / EBITDA 23.5 x 29.5 x 33.8 x 26.8 x 25.3 x 20.7 x 18.4 x 16.4 x
EV / FCF 47.7 x 40.3 x 57.2 x 144 x 58.1 x 29.2 x 25.8 x 22.6 x
FCF Yield 2.1% 2.48% 1.75% 0.69% 1.72% 3.42% 3.88% 4.42%
Price to Book 8.43 x 11.1 x 12.4 x 9.35 x 7.76 x 6.56 x 5.49 x 4.57 x
Nbr of stocks (in thousands) 143,393 144,668 145,640 146,405 147,062 146,907 - -
Reference price 2 122.0 192.0 246.5 209.6 218.5 218.1 218.1 218.1
Announcement Date 7/25/19 8/5/20 8/5/21 8/11/22 8/3/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Juni 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,607 2,957 3,197 3,578 4,223 4,670 5,023 5,377
EBITDA 1 792.1 966 1,074 1,162 1,317 1,572 1,726 1,873
EBIT 1 641.3 811.2 903.7 1,000 1,224 1,454 1,619 1,769
Operating Margin 24.6% 27.43% 28.27% 27.96% 28.99% 31.13% 32.24% 32.91%
Earnings before Tax (EBT) 1 518.8 733.1 883.7 960.5 1,102 1,310 1,493 1,630
Net income 1 404.6 621.7 474.5 779.4 897.6 1,023 1,217 1,349
Net margin 15.52% 21.02% 14.84% 21.78% 21.25% 21.91% 24.24% 25.09%
EPS 2 2.800 4.270 3.240 5.300 6.090 6.937 8.115 8.956
Free Cash Flow 1 390.3 706.9 634 216.3 573.6 1,114 1,230 1,358
FCF margin 14.98% 23.91% 19.83% 6.05% 13.58% 23.85% 24.49% 25.26%
FCF Conversion (EBITDA) 49.28% 73.18% 59.01% 18.62% 43.55% 70.86% 71.25% 72.51%
FCF Conversion (Net income) 96.48% 113.71% 133.61% 27.75% 63.91% 108.84% 101.03% 100.65%
Dividend per Share 2 1.500 1.560 1.560 1.680 1.800 1.961 2.145 2.239
Announcement Date 7/25/19 8/5/20 8/5/21 8/11/22 8/3/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 894.9 864.5 914.7 950.3 1,034 1,117 1,122 1,102 1,163 1,197 1,213 1,169 1,234 1,268 1,305
EBITDA 1 289.5 276.6 294.7 312.8 326.4 345 333 363.7 390.5 418.1 426.6 398 430.4 451.2 464.6
EBIT 1 248.7 234.3 255.4 290.8 305.5 321.2 307 318.8 365.5 393.6 391.1 374.1 407.2 420.4 425
Operating Margin 27.79% 27.1% 27.92% 30.6% 29.55% 28.76% 27.36% 28.92% 31.43% 32.88% 32.25% 32% 33% 33.15% 32.58%
Earnings before Tax (EBT) 1 237.3 226.3 238.1 261.8 273.7 289.4 276.8 272.2 259.5 375.4 358.5 352.7 378.3 392.5 398
Net income 1 201.8 179 195.1 210.5 224.9 232.5 229.7 219.4 208.8 300.5 292.7 279.6 303.4 314.5 320
Net margin 22.55% 20.71% 21.32% 22.15% 21.76% 20.82% 20.47% 19.91% 17.96% 25.1% 24.13% 23.92% 24.59% 24.8% 24.53%
EPS 2 1.370 1.220 1.330 1.430 1.530 1.580 1.560 1.490 1.420 2.040 1.987 1.875 2.025 2.095 2.165
Dividend per Share 2 0.4200 0.4200 0.4200 0.4400 0.4400 0.4400 0.4800 0.4800 0.4800 - 0.4947 0.5202 0.5202 0.5202 0.5202
Announcement Date 1/27/22 4/28/22 8/11/22 10/27/22 1/26/23 4/27/23 8/3/23 10/26/23 1/24/24 4/25/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 1,124 713 360 502 1,213 522 - -
Net Cash position 1 - - - - - - 354 1,331
Leverage (Debt/EBITDA) 1.419 x 0.738 x 0.3352 x 0.4317 x 0.9211 x 0.3324 x - -
Free Cash Flow 1 390 707 634 216 574 1,114 1,230 1,358
ROE (net income / shareholders' equity) 25.5% 27.2% 29% 27.2% 25.4% 24.3% 24.1% 22.9%
ROA (Net income/ Total Assets) 14.7% 14.3% 16.8% 17.3% 16% 16.9% 17.7% 17.6%
Assets 1 2,756 4,348 2,831 4,500 5,598 6,069 6,864 7,658
Book Value Per Share 2 14.50 17.30 19.90 22.40 28.10 33.30 39.70 47.70
Cash Flow per Share 2 3.180 5.510 5.030 2.390 4.700 8.530 9.190 10.80
Capex 1 68.7 95.3 103 135 120 119 130 144
Capex / Sales 2.64% 3.22% 3.21% 3.77% 2.83% 2.54% 2.59% 2.67%
Announcement Date 7/25/19 8/5/20 8/5/21 8/11/22 8/3/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for ResMed, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
218.1 USD
Average target price
215.1 USD
Spread / Average Target
-1.38%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
RESMED, INC. Stock ResMed, Inc.
+26.76% 32.03B
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.07% 219B
DANAHER CORPORATION Stock Danaher Corporation
+6.59% 183B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.26% 133B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.57% 108B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+0.65% 63.06B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+13.35% 52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-0.62% 48.2B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-0.93% 40.37B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+11.54% 39.35B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. RMD Stock
  4. Financials ResMed, Inc.